Jacobs Levy Equity Management Inc. Lowers Stake in Bioventus Inc. (NYSE:BVS)

Jacobs Levy Equity Management Inc. reduced its position in Bioventus Inc. (NYSE:BVS - Free Report) by 34.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 195,608 shares of the company's stock after selling 102,407 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.24% of Bioventus worth $2,338,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC acquired a new position in Bioventus during the third quarter worth about $51,000. Covestor Ltd acquired a new position in shares of Bioventus during the 3rd quarter worth approximately $69,000. CWM LLC purchased a new stake in Bioventus in the 3rd quarter valued at approximately $89,000. HB Wealth Management LLC purchased a new stake in Bioventus in the 2nd quarter valued at approximately $60,000. Finally, Mackenzie Financial Corp purchased a new position in Bioventus during the second quarter worth $77,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Trading Up 0.3 %

BVS stock traded up $0.04 during midday trading on Friday, hitting $11.68. The stock had a trading volume of 198,975 shares, compared to its average volume of 366,763. The company's 50-day moving average price is $12.14 and its 200 day moving average price is $9.37. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm has a market cap of $947.83 million, a PE ratio of -19.15 and a beta of 0.79. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38.

Bioventus (NYSE:BVS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, meeting analysts' consensus estimates of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The business had revenue of $138.96 million during the quarter, compared to the consensus estimate of $132.57 million. During the same quarter in the previous year, the business earned $0.05 earnings per share. On average, equities research analysts predict that Bioventus Inc. will post 0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BVS. Craig Hallum upped their price objective on Bioventus from $12.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, September 27th. Canaccord Genuity Group boosted their target price on shares of Bioventus from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.